MRI-Based Texture Analysis for Preoperative Prediction of BRAF V600E Mutation in Papillary Thyroid Carcinoma

References

• Megwalu UC, Moon PK. Thyroid cancer incidence and mortality trends in the United States: 2000–2018. Thyroid. 2022;32(5):560–570.
   PubMed Web of Science ®Google Scholar
• Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72(5):409–436. doi:10.3322/caac.21731
   PubMed Web of Science ®Google Scholar
• Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. doi:10.1089/thy.2015.0020
   PubMed Web of Science ®Google Scholar
• Ito Y, Kudo T, Kobayashi K, Miya A, Ichihara K, Miyauchi A. Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5768 patients with average 10-year follow-up. World J Surg. 2012;36(6):1274–1278. doi:10.1007/s00268-012-1423-5
   PubMed Web of Science ®Google Scholar
• Popadich A, Levin O, Lee JC, et al. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery. 2011;150(6):1048–1057. doi:10.1016/j.surg.2011.09.003
   PubMed Web of Science ®Google Scholar
• Kwak JY, Kim EK, Chung WY, Moon HJ, Kim MJ, Choi JR. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology. 2009;253(3):854–860. doi:10.1148/radiol.2533090471
   PubMed Web of Science ®Google Scholar
• Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28(7):742–762. doi:10.1210/er.2007-0007
   PubMed Web of Science ®Google Scholar
• Chen Z, Wang W, Xu J, et al. Tumor mutation burden-assisted risk stratification for papillary thyroid cancer. Endocrine. 2022;78(2):296–305. doi:10.1007/s12020-022-03154-0
   PubMed Web of Science ®Google Scholar
• Kurtulmus N, Ertas B, Saglican Y, Kaya H, Ince U, Duren M. BRAF(V600E) mutation: has it a role in cervical lymph node metastasis of papillary thyroid cancer? Eur Thyroid J. 2016;5(3):195–200. doi:10.1159/000448112
   PubMed Web of Science ®Google Scholar
• Subash A, Sinha P, Singh A. BRAF mutation and age in differentiated thyroid cancer risk stratification: two sides of the same coin. Oral Oncol. 2020;106:104732. doi:10.1016/j.oraloncology.2020.104732
   PubMed Web of Science ®Google Scholar
• Yan C, Huang M, Li X, Wang T, Ling R. Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma. Endocr Connect. 2019;8(7):988–996. doi:10.1530/EC-19-0246
   PubMed Web of Science ®Google Scholar
• Zhao CK, Zheng JY, Sun LP, Xu RY, Wei Q, Xu HX. BRAF(V600E) mutation analysis in fine-needle aspiration cytology specimens for diagnosis of thyroid nodules: the influence of false-positive and false-negative results. Cancer Med. 2019;8(12):5577–5589. doi:10.1002/cam4.2478
   PubMed Web of Science ®Google Scholar
• Tessler FN, Middleton WD, Grant EG, et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): white paper of the ACR TI-RADS committee. J Am Coll Radiol. 2017;14(5):587–595. doi:10.1016/j.jacr.2017.01.046
   PubMed Web of Science ®Google Scholar
• Liu Y, He L, Yin G, et al. Association analysis and the clinical significance of BRAF gene mutations and ultrasound features in papillary thyroid carcinoma. Oncol Lett. 2019;18(3):2995–3002. doi:10.3892/ol.2019.10641
   PubMed Web of Science ®Google Scholar
• Xu JM, Chen YJ, Dang YY, Chen M. Association between preoperative US, elastography features and prognostic factors of papillary thyroid cancer with BRAF(V600E) Mutation. Front Endocrinol. 2019;10:902. doi:10.3389/fendo.2019.00902
   PubMed Web of Science ®Google Scholar
• Hwang J, Shin JH, Han BK, et al. Papillary thyroid carcinoma with BRAFV600E mutation: sonographic prediction. AJR Am J Roentgenol. 2010;194(5):W425–W430. doi:10.2214/AJR.09.3512
   PubMed Web of Science ®Google Scholar
• Li Q, Yuan J, Wang Y, Zhai Y. Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma. Oncol Lett. 2017;14(2):1439–1444. doi:10.3892/ol.2017.6276
   PubMed Web of Science ®Google Scholar
• Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749–762. doi:10.1038/nrclinonc.2017.141
   PubMed Web of Science ®Google Scholar
• Kwon MR, Shin JH, Park H, Cho H, Hahn SY, Park KW. Radiomics study of thyroid ultrasound for predicting BRAF mutation in papillary thyroid carcinoma: preliminary results. Am J Neuroradiol. 2020;41(4):700–705. doi:10.3174/ajnr.A6505
   PubMed Web of Science ®Google Scholar
• Yoon JH, Han K, Lee E, et al. Radiomics in predicting mutation status for thyroid cancer: a preliminary study using radiomics features for predicting BRAFV600E mutations in papillary thyroid carcinoma. PLoS One. 2020;15(2):e0228968. doi:10.1371/journal.pone.0228968
   PubMed Web of Science ®Google Scholar
• Wang H, Liu K, Ren J, Liu W, Chen Y, Song B. Magnetic resonance imaging characteristics of papillary thyroid carcinoma for the prediction of cervical central compartment lymph node metastasis. J Comput Assist Tomogr. 2019;43(6):963–969. doi:10.1097/RCT.0000000000000883
   PubMed Web of Science ®Google Scholar
• Wang H, Wei R, Liu W, Chen Y, Song B. Diagnostic efficacy of multiple MRI parameters in differentiating benign vs. malignant thyroid nodules. BMC Med Imaging. 2018;18(1):50. doi:10.1186/s12880-018-0294-0
   PubMedGoogle Scholar
• Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381(9871):1058–1069. doi:10.1016/S0140-6736(13)60109-9
   PubMed Web of Science ®Google Scholar
• Goh X, Lum J, Yang SP, et al. BRAF mutation in papillary thyroid cancer-prevalence and clinical correlation in a South-East Asian cohort. Clin Otolaryngol. 2019;44(2):114–123. doi:10.1111/coa.13238
   PubMed Web of Science ®Google Scholar
• Li XJ, Mao XD, Chen GF, et al. High BRAFV600E mutation frequency in Chinese patients with papillary thyroid carcinoma increases diagnostic efficacy in cytologically indeterminate thyroid nodules. Medicine. 2019;98(28):e16343. doi:10.1097/MD.0000000000016343
   PubMed Web of Science ®Google Scholar
• Pessoa-Pereira D, Medeiros M, Lima VMS, et al. Association between BRAF (V600E) mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series. Arch Endocrinol Metab. 2019;63(2):97–106. doi:10.20945/2359-3997000000120
   PubMed Web of Science ®Google Scholar
• Johnson SJ, Hardy SA, Roberts C, Bourn D, Mallick U, Perros P. Pilot of BRAF mutation analysis in indeterminate, suspicious and malignant thyroid FNA cytology. Cytopathology. 2014;25(3):146–154. doi:10.1111/cyt.12125
   PubMed Web of Science ®Google Scholar
• Rossi ED, Adeniran AJ, Faquin WC. Pitfalls in thyroid cytopathology. Surg Pathol Clin. 2019;12(4):865–881. doi:10.1016/j.path.2019.08.001
   PubMedGoogle Scholar
• Patel KN, Yip L, Lubitz CC, et al. The American association of endocrine surgeons guidelines for the definitive surgical management of thyroid disease in adults. Ann Surg. 2020;271(3):e21–e93. doi:10.1097/SLA.0000000000003580
   PubMed Web of Science ®Google Scholar
• Arora C, Kaur D, Naorem LD, Raghava GPS, Murugan AK. Prognostic biomarkers for predicting papillary thyroid carcinoma patients at high risk using nine genes of apoptotic pathway. PLoS One. 2021;16(11):e0259534. doi:10.1371/journal.pone.0259534
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Ryder M, Jimenez C. Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev. 2019;40(6):1573–1604. doi:10.1210/er.2019-00007
   PubMed Web of Science ®Google Scholar
• Zarkesh M, Zadeh-Vakili A, Akbarzadeh M, et al. BRAF V600E mutation and microRNAs are helpful in distinguishing papillary thyroid malignant lesions: tissues and fine needle aspiration cytology cases. Life Sci. 2019;223:166–173. doi:10.1016/j.lfs.2019.03.034
   PubMed Web of Science ®Google Scholar
• Li X, Li E, Du J, Wang J, Zheng B. BRAF mutation analysis by ARMS-PCR refines thyroid nodule management. Clin Endocrinol. 2019;91(6):834–841. doi:10.1111/cen.14079
   PubMed Web of Science ®Google Scholar
• Kabaker AS, Tublin ME, Nikiforov YE, et al. Suspicious ultrasound characteristics predict BRAF V600E-positive papillary thyroid carcinoma. Thyroid. 2012;22(6):585–589. doi:10.1089/thy.2011.0274
   PubMed Web of Science ®Google Scholar
• Lin ZM, Yan CX, Song Y, et al. The features of contrast enhanced ultrasound and BRAF V600E in papillary thyroid carcinoma. J Thorac Dis. 2019;11(12):5071–5078. doi:10.21037/jtd.2019.11.78
   PubMed Web of Science ®Google Scholar
• Shofty B, Artzi M, Shtrozberg S, et al. Virtual biopsy using MRI radiomics for prediction of BRAF status in melanoma brain metastasis. Sci Rep. 2020;10(1):6623. doi:10.1038/s41598-020-63821-y
   PubMed Web of Science ®Google Scholar
• Wan L, Peng W, Zou S, et al. Predicting perineural invasion using histogram analysis of zoomed EPI diffusion-weighted imaging in rectal cancer. Abdom Radiol. 2022;47(10):3353–3363. doi:10.1007/s00261-022-03579-1
   PubMed Web of Science ®Google Scholar
• Yue Q, Yu Y, Shi Z, et al. Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features. J Neurosurg. 2018;129(1):27–34. doi:10.3171/2017.4.JNS163113
   PubMed Web of Science ®Google Scholar
• Song F, Song L, Xing T, et al. A multi-classification model for predicting the invasiveness of lung adenocarcinoma presenting as pure ground-glass nodules. Front Oncol. 2022;12:800811. doi:10.3389/fonc.2022.800811
   PubMed Web of Science ®Google Scholar